ACRS
Aclaris Therapeutics Inc
NASDAQ: ACRS · HEALTHCARE · BIOTECHNOLOGY
$4.47
+5.92% today
Updated 2026-04-29
Market cap
$624.30M
P/E ratio
—
P/S ratio
79.77x
EPS (TTM)
$-0.53
Dividend yield
—
52W range
$1 – $5
Volume
2.0M
WallStSmart proprietary scores
20
out of 100
Grade: F
Strong Sell
Investment rating
2.7
Growth
F6.5
Quality
B2.5
Profitability
F6.7
Valuation
B2/9
Piotroski F-Score
Weak
-4.7
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →200 stocks currently score above 75
Price targets
Analyst target
$8.38
+87.47%
12-Month target
—
—
Intrinsic (DCF)
$6.88
Margin of safety
+50.73%
1 Strong Buy6 Buy1 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ 50.73% below intrinsic value
+ Debt/equity 0.02x — low leverage
Risks
- Piotroski 2/9 — weak financial health
- Altman Z -4.72 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-13.18M
- Revenue declining -85.90% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $29.75M | $31.25M | $18.72M | $7.83M | $7.83M |
| Net income | $-86.91M | $-88.48M | $-132.06M | $-64.92M | $-19.80M |
| EPS | — | — | — | — | $-0.53 |
| Free cash flow | $-68.17M | $-79.63M | $-20.20M | $-47.22M | $-13.18M |
| Profit margin | -292.11% | -283.15% | -705.48% | -829.58% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-01 | BALTHASER, KEVIN | Sale | 2,375 | — |
| 2026-03-01 | BALTHASER, KEVIN | Buy | 2,375 | — |
| 2026-03-01 | BALTHASER, KEVIN | Sale | 677 | $2.87 |
Peer comparison
Smart narrative
Aclaris Therapeutics Inc trades at $4.47. Our Smart Value Score of 20/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -4.72, it sits in the distress. TTM revenue stands at $7.83M. Our DCF model estimates intrinsic value at $6.88.
Frequently asked questions
What is Aclaris Therapeutics Inc's stock price?
Aclaris Therapeutics Inc (ACRS) trades at $4.47.
Is Aclaris Therapeutics Inc overvalued?
Smart Value Score 20/100 (Grade F, Strong Sell). DCF value $6.88.
What is the price target of Aclaris Therapeutics Inc (ACRS)?
The analyst target price is $8.38, representing +87.5% upside from the current price of $4.47.
What is the intrinsic value of Aclaris Therapeutics Inc (ACRS)?
Based on our DCF model, intrinsic value is $6.88, a +50.7% margin of safety versus $4.47.
What is Aclaris Therapeutics Inc's revenue?
TTM revenue is $7.83M.
Piotroski F-Score?
2/9 — weak financial health.
Altman Z-Score?
-4.72 — distress.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio79.77x
ROE-50.20%
Beta0.68
50D MA$3.70
200D MA$2.74
Shares out0.14B
Float0.08B
Short ratio—
Avg volume2.0M
Performance
1 week+5.76%
1 month+25.28%
3 months+13.95%
YTD+46.51%
1 year—
3 years—
5 years—